JP2023506147A5 - - Google Patents

Info

Publication number
JP2023506147A5
JP2023506147A5 JP2022532865A JP2022532865A JP2023506147A5 JP 2023506147 A5 JP2023506147 A5 JP 2023506147A5 JP 2022532865 A JP2022532865 A JP 2022532865A JP 2022532865 A JP2022532865 A JP 2022532865A JP 2023506147 A5 JP2023506147 A5 JP 2023506147A5
Authority
JP
Japan
Application number
JP2022532865A
Other languages
Japanese (ja)
Other versions
JP2023506147A (ja
JP7765088B2 (ja
JPWO2021111124A5 (https=
Filing date
Publication date
Priority claimed from GBGB1917603.1A external-priority patent/GB201917603D0/en
Priority claimed from GBGB2015692.3A external-priority patent/GB202015692D0/en
Priority claimed from GBGB2015820.0A external-priority patent/GB202015820D0/en
Priority claimed from PCT/GB2020/053081 external-priority patent/WO2021111124A1/en
Application filed filed Critical
Publication of JP2023506147A publication Critical patent/JP2023506147A/ja
Publication of JPWO2021111124A5 publication Critical patent/JPWO2021111124A5/ja
Publication of JP2023506147A5 publication Critical patent/JP2023506147A5/ja
Priority to JP2025175449A priority Critical patent/JP2026027269A/ja
Publication of JP7765088B2 publication Critical patent/JP7765088B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022532865A 2019-12-02 2020-12-01 Mettl3阻害剤としてのポリヘテロ環式化合物 Active JP7765088B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025175449A JP2026027269A (ja) 2019-12-02 2025-10-17 Mettl3阻害剤としてのポリヘテロ環式化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1917603.1A GB201917603D0 (en) 2019-12-02 2019-12-02 Inhibitory compounds
GB1917603.1 2019-12-02
GBGB2015692.3A GB202015692D0 (en) 2020-10-02 2020-10-02 Inhibitory compounds
GB2015692.3 2020-10-02
GB2015820.0 2020-10-06
GBGB2015820.0A GB202015820D0 (en) 2020-10-06 2020-10-06 Inhibitory compounds
PCT/GB2020/053081 WO2021111124A1 (en) 2019-12-02 2020-12-01 Polyheterocyclic compounds as mettl3 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025175449A Division JP2026027269A (ja) 2019-12-02 2025-10-17 Mettl3阻害剤としてのポリヘテロ環式化合物

Publications (4)

Publication Number Publication Date
JP2023506147A JP2023506147A (ja) 2023-02-15
JP2023506147A5 true JP2023506147A5 (https=) 2023-12-07
JPWO2021111124A5 JPWO2021111124A5 (https=) 2023-12-07
JP7765088B2 JP7765088B2 (ja) 2025-11-06

Family

ID=73854829

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532865A Active JP7765088B2 (ja) 2019-12-02 2020-12-01 Mettl3阻害剤としてのポリヘテロ環式化合物
JP2025175449A Pending JP2026027269A (ja) 2019-12-02 2025-10-17 Mettl3阻害剤としてのポリヘテロ環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025175449A Pending JP2026027269A (ja) 2019-12-02 2025-10-17 Mettl3阻害剤としてのポリヘテロ環式化合物

Country Status (11)

Country Link
US (3) US12195458B2 (https=)
EP (1) EP4069694A1 (https=)
JP (2) JP7765088B2 (https=)
KR (1) KR20220113431A (https=)
CN (1) CN115151540A (https=)
AU (1) AU2020394867A1 (https=)
BR (1) BR112022010561A2 (https=)
CA (1) CA3162166A1 (https=)
IL (1) IL293340A (https=)
MX (1) MX2022006700A (https=)
WO (1) WO2021111124A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113905787A (zh) * 2019-04-05 2022-01-07 斯托姆治疗有限公司 Mettl3抑制化合物
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
US20230391770A1 (en) * 2020-10-06 2023-12-07 Storm Therapeutics Limited Mettl3 inhibitory compounds
GB202107905D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Processes for the preparation of inhibitory compounds
GB202107907D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
CN115894447B (zh) * 2021-09-22 2024-10-01 成都先导药物开发股份有限公司 Mettl3抑制剂及其用途
CN116514805A (zh) * 2021-12-10 2023-08-01 成都先导药物开发股份有限公司 Mettl3抑制剂化合物
WO2023129933A2 (en) * 2021-12-29 2023-07-06 858 Therapeutics, Inc. 6,6-fused heterocyclic compounds as mettl3 inhibitors
US20250145627A1 (en) 2022-02-11 2025-05-08 Xizang Haisco Pharmaceutical Co., Ltd. METTL3 Inhibitor and Composition, and Application of Same in Medicine
WO2023235756A1 (en) * 2022-05-31 2023-12-07 The Trustees Of The University Of Pennsylvania Compounds for the treatment of hiv
JP2025530847A (ja) * 2022-09-16 2025-09-17 北京華益健康薬物研究中心 Mettl3阻害剤化合物、その医薬組成物及び用途
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
WO2024153775A1 (en) 2023-01-20 2024-07-25 Epics Therapeutics Piperidine derivatives as mettl3 inhibitors
WO2024200835A1 (en) 2023-03-30 2024-10-03 Novalix Novel mettl3 inhibitors and use thereof in therapy
CN119899188A (zh) * 2023-10-26 2025-04-29 杭州邦顺制药有限公司 Mettl3抑制剂
GB202316595D0 (en) 2023-10-30 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
GB202316683D0 (en) 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025242921A1 (en) 2024-05-23 2025-11-27 Storm Therapeutics Limited Processes for the preparation of inhibitory compounds
CN121735955A (zh) * 2024-09-25 2026-03-27 中国科学院上海药物研究所 稠合双环类化合物及其制备方法、组合物和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
FR2734814B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
US5928323A (en) 1996-05-30 1999-07-27 Sun Microsystems, Inc. Apparatus and method for dynamically generating information with server-side software objects
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0966461A1 (en) 1997-03-21 1999-12-29 Novartis AG Pyrazole derivatives as herbicides
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1492874A (zh) 2000-12-21 2004-04-28 大环内酯
IL157412A0 (en) 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
US7169795B2 (en) 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 c-반응성 단백질을감소시키는 방법
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
WO2006138549A1 (en) 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
CA2622639C (en) 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
KR20080064173A (ko) 2005-10-21 2008-07-08 글락소 그룹 리미티드 항균제로서 유용한 페리 축합 트리시클릭 화합물
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CN102633783A (zh) * 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
CA2656825C (en) 2006-06-22 2013-12-10 Prana Biotechnology Limited Method of treatment and agents useful for same
WO2008016666A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US8202524B2 (en) * 2006-08-31 2012-06-19 Sk Chemicals Co., Ltd. Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
KR20090097194A (ko) 2006-12-22 2009-09-15 아벡사 리미티드 바이사이클 피리미디논 및 그 용도
CN101636398A (zh) * 2007-02-05 2010-01-27 泽农医药公司 用于治疗钠通道介导的疾病或疾病状态的吡啶并嘧啶酮化合物
WO2008100448A2 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
CN101801965B (zh) 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
WO2009127678A1 (en) * 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
CN102089297A (zh) * 2008-06-06 2011-06-08 雅培制药有限公司 新的1,2,4-噁二唑化合物和其使用方法
JP5539978B2 (ja) 2008-07-02 2014-07-02 アベキサ・リミテッド チアゾピリミジノンおよびその使用
EP2291377B1 (en) 2008-07-02 2015-02-18 Avexa Limited Imidazopyrimidinones and uses thereof
CN102143962B (zh) 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
WO2010074101A1 (ja) * 2008-12-25 2010-07-01 住友化学株式会社 アミノピリジン化合物及びその用途
WO2010114898A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
EP2435080A2 (en) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN102336751A (zh) 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
EP2812004B1 (en) 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2014063199A1 (en) * 2012-10-26 2014-05-01 Akaal Pharma Pty Ltd Organic compounds
EP2977464A4 (en) 2013-03-19 2016-10-19 Toppan Printing Co Ltd PROCEDURE FOR PREDICTING SENSITIVITY TO EGFR HEMMER
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
BR112016029825B1 (pt) 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto
AU2015276699B2 (en) 2014-06-17 2019-10-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor
JP6546654B2 (ja) 2014-08-22 2019-07-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 淋菌感染を治療するための三環式含窒素化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
WO2017070464A1 (en) * 2015-10-22 2017-04-27 Memorial Sloan-Kettering Cancer Center Cofactor analogs as methyltransferase inhibitors for treating cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10730903B2 (en) * 2016-09-19 2020-08-04 Memorial Sloan-Kettering Cancer Center Adenosine analogs as methyltransferase inhibitors for treating cancer
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
MX390512B (es) 2017-03-26 2025-03-20 Takeda Pharmaceuticals Co Carboxamidas heteroaromáticas sustituidas con piperidinilo y piperazinilo como moduladores de gpr6.
CN107349217B (zh) * 2017-07-21 2020-06-09 深圳大学 一种基于mettl3的小干扰rna及其药物和应用
EP3589745A1 (en) * 2018-04-11 2020-01-08 Chemestmed Ltd. A method of modulating the rna methylation
CN112585119A (zh) 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
SG11202105325QA (en) 2018-11-30 2021-06-29 Epizyme Inc Methods of treating whsc1-overexpressing cancers by inhibiting setd2
CN113905787A (zh) * 2019-04-05 2022-01-07 斯托姆治疗有限公司 Mettl3抑制化合物
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors

Similar Documents

Publication Publication Date Title
JP2022528562A5 (https=)
JP2023506147A5 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)